Showing results (781-790 of 1,395) with videos related to

Sort By:
Pageof 140
JCO Precision Oncology|October 14, 2022
Histology-Specific Prognostication for Radiation-Associated Soft Tissue SarcomaEdmund K Bartlett, Avinash Sharma, Kenneth Seier, et al.
JCO Precision Oncology|October 6, 2022
Outcomes With Local Therapy and Tyrosine Kinase Inhibition in Patients With ALK/ROS1/RET-Rearranged Lung CancersHarper Hubbeling, Noura Choudhury, Jessica Flynn, et al.
JCO Precision Oncology|October 6, 2022
BRCA1/2 Variants Identified Through Tumor Genomic Profiling: Assessing Genetic Counseling OutcomesJamie W Harriman, Whitney F Espinel, Jennie Vagher, et al.
JCO Precision Oncology|October 20, 2022
Germline Testing and Somatic Tumor Testing for BRCA1/2 Pathogenic Variants in Ovarian Cancer: What Is the Optimal Sequence of Testing?Janice S Kwon, Anna V Tinker, Jennifer Santos, et al.
JCO Precision Oncology|October 20, 2022
Quantifying the Value of the Molecular Tumor Board: Discordance Recommendation Rate and Drug Cost AvoidanceMary K Walters, Andrew T Ackerman, James L Weese, et al.
JCO Precision Oncology|October 30, 2018
Clinical Utility of Rapid EGFR Genotyping in Advanced Lung CancerIbiayi Dagogo-Jack, Christopher G Azzolli, Florian Fintelmann, et al.
JCO Precision Oncology|November 22, 2021
Quantification of Discordant Variant Interpretations in a Large Family-Based Study of Li-Fraumeni SyndromeMegan N Frone, Douglas R Stewart, Sharon A Savage, et al.
JCO Precision Oncology|April 6, 2019
Translating in vivo metabolomic analysis of succinate dehydrogenase deficient tumours into clinical utilityRuth T Casey, Mary A McLean, Basetti Madhu, et al.
JCO Precision Oncology|January 27, 2025
Clinical Activity of Mitogen-Activated Protein Kinase Inhibitors in Patients With MAP2K1 (MEK1)-Mutated Metastatic CancersMatthew Dankner, Emmanuelle Rousselle, Sarah Petrecca, et al.
Pageof 140